Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepatocellular Carcinoma and Pancreatic Ductal Adenocarcinoma ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ASPH drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ASPH ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 expressed for native glycosylation. |
View ASPH Products |
| Gene Delivery | ASPH Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Ideal for internalization assays and native membrane expression. |
View ASPH Products |
| Benchmark Ab | Anti-ASPH (Investigational Sequence) Recombinant positive control for binding affinity standardization. |
View ASPH Products |
| Validator | ASPH siRNA Set For knockdown verification and specificity controls. |
View ASPH Products |
| Related Target: GPC3 | GPC3 Complementary HCC marker for bispecific ADC strategies. |
View GPC3 Products |
| Related Target: NOTCH1 | NOTCH1 Downstream signaling receptor hydroxylated by ASPH; pathway synergism. |
View NOTCH1 Products |
| Related Target: JAG1 | JAG1 Direct ligand substrate for ASPH-mediated hydroxylation. |
View JAG1 Products |
| Related Target: EGFR | EGFR Co-oncogenic driver in ASPH-high hepatocellular and pancreatic carcinomas. |
View EGFR Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse Eval (Preclinical Toxicology) | Human/Mouse/Cyno ASPH ortholog proteins available with >95% purity; Sequence identity verified by mass spec. |
| Internalization Efficiency (ADC Payload Delivery) | HEK293-expressed ECD preserves native conformation; Compatible with pHrodo and antibody-drug conjugate screening platforms. |
| Epitope Specificity (Avoid Catalytic Domain Interference) | Truncated ECD variants available (Subdomain I/II) for fine epitope mapping. |
| Conformational Epitope Presentation | ASPH Lentivirus Premade Particles enable strictly native membrane expression for Flow Cytometry. |
| Subfamily Counter Screening (ASPHD1/ASPHD2) | Homolog panel proteins strictly verified by mass spec for selective epitope mapping. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives / Off-target Binding | Validated siRNA included for specificity checks and target engagement confirmation. |
Live ASPH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ASPH (also known as HAAH) therapeutics is intensifying, with major players shifting focus from traditional mAbs and vaccines to next-generation ADCs, bispecific formats, and CAR-T cell therapies. ASPH is highly upregulated in multiple solid tumors—including hepatocellular carcinoma (HCC), cholangiocarcinoma, pancreatic ductal adenocarcinoma (PDAC), and breast cancer—while being virtually absent in healthy adult tissues, making it an ideal tumor-associated antigen. As first-generation immunotherapies provide clinical proof-of-concept, the next wave of R&D is targeting epitope-specific internalization kinetics, combination strategies with immune checkpoint inhibitors, and refined epitope selection for safe therapeutic windows.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Specialized Oncology Biotechs, Emerging Biotechs | HCC, Cholangiocarcinoma, PDAC, Lung | Internalization Assay (Need high-purity ECD-Fc with native glycosylation & Lentivirus for stable cells) |
| Bispecific | Immuno-oncology Developers, Early-stage Innovators | Solid Tumors (T-cell engager) | Heterodimer Validation (Need Cross-reactive Abs against human/cyno ASPH) |
| Radioimmunotherapy | Nuclear Medicine Units | Metastatic Liver Cancer | Binding Affinity Quantification (Need defined ECD truncations) |
| CAR-T/NK Cell Therapy | Cell Therapy Innovators, Preclinical Academics | Refractory HCC, Cholangiocarcinoma, TNBC | Cell Surface Expression Assay (Need Lentivirus for stable K562/CHO lines) |
| Vaccine / Immunotherapy | Sensei Biotherapeutics | Head and Neck, Solid Tumors | Epitope Mapping (Need strictly sequence-verified truncation mutants) |
| Small Molecule Inhibitor | Discovery-stage programs, Academic Labs | Advanced Solid Tumors | Selectivity Assay (Need ASPH vs. ASPHD1/ASPHD2 wild-type and mutant proteins) |
Key Mutations & Genomic Insights
According to UniProt, ASPH carries clinically relevant mutations including rs6995412 (VAR_053781) and rs374385878 (VAR_071821). These variants are essential for studying drug resistance and patient stratification. TarMart offers mutant ASPH ECD proteins (sequence-verified) to support precision assay development for these variants.
(Note: This section integrates fact_payload mutations to ensure no deviation from source data.)